Edward Paraiso
Urology · Trumbull, CTNPI 1740212141
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Procept Biorobotics Corporation at 26.8% of the total. Reporting peaked in 2019 at $2,478 and has fallen 89.0% since, to $272 in 2023.
Across 101 payments — averaging $40.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$1K
- Neotract Inc.$921
- Astellas Pharma US Inc$388
- Coloplast$345
- Pfizer$209
- Johnson & Johnson$156
- plus $944 from 18 others
What the payments were for
- Travel & lodging$1,45336%
- Food & beverage$1,88447%
- Education$70817%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 6 | $1,083 |
| Neotract Inc. | 2 | $921 |
| Astellas Pharma US Inc | 19 | $388 |
| Coloplast | 12 | $345 |
| Pfizer | 10 | $209 |
| Johnson & Johnson | 6 | $156 |
| Endo Pharmaceuticals Inc. | 5 | $138 |
| Ferring Pharmaceuticals Inc. | 8 | $127 |
| AbbVie(2 entities) | 6 | $124 |
| Amgen | 7 | $99 |
| Rochester Medical Corporation | 3 | $94 |
| Teleflex LLC | 1 | $81 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $41 |
| Bard Access Systems, Inc. | 1 | $39 |
| Therapeuticsmd, Inc. | 2 | $35 |
| Bayer | 2 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Boston Scientific | 1 | $18 |
| Dentsply IH Inc. | 1 | $18 |
| Mission Pharmacal Company | 1 | $17 |
| Ambu Inc. | 2 | $17 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,025
- UroLift$921
How this compares
$4,045 in reported general payments places this provider in the 65th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 352 | $393,831 |
| XtandiEnzalutamide | 24 | $346,902 |
| MyrbetriqMirabegron | 243 | $210,464 |
| Tamsulosin Hcl | 981 | $13,817 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 677 | $13,709 |
| ElmironPentosan Polysulfate Sodium | 11 | $11,211 |
| Mirabegron ErMirabegron | 11 | $7,884 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 61 | $7,450 |
| Solifenacin Succinate | 206 | $7,047 |
| Dutasteride | 200 | $6,751 |
| Tolterodine Tartrate ErTolterodine Tartrate | 55 | $6,518 |
| Finasteride | 428 | $6,080 |
| Trospium Chloride ErTrospium Chloride | 44 | $5,957 |
| Potassium Citrate ErPotassium Citrate | 74 | $5,665 |
| Darifenacin ErDarifenacin Hydrobromide | 23 | $4,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $388 | $557,366267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 156 urology providers in Connecticut.
Other urology in Trumbull
- Benjamin RudnickTrumbull$4K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.